OncoMatch/Clinical Trials/NCT06730295
Elimination of PTV Margins Based on Online Adaptive Stereotactic Radiotherapy for Centrally Located Early-stage Non-small Cell Lung Cancer
Is NCT06730295 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies non-drug interventions for lung cancer (nsclc).
This study aims to explore the safety and efficacy of eliminating the PTV (planning target volume) margins based on online adaptive stereotactic radiotherapy for patients with centrally located early-stage non-small cell lung cancer (NSCLC).
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Disease stage
Required: Stage T1-2N0M0, RT1-2N0M0
untreated early-stage non-small cell lung cancer (T1-2N0M0), or recurrent disease (rT1-2N0M0) that is inoperable or where the patient is unwilling to undergo surgery
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Lab requirements
Blood counts
serum hemoglobin ≥ 80 g/l, platelets ≥ 100,000/μl, absolute neutrophil count ≥ 1,500/μl
Kidney function
serum creatinine ≤ 1.25 times the upper normal limit (unl) or creatinine clearance ≥ 60 ml/min
Liver function
serum bilirubin ≤ 1.5 times unl, ast (sgot) and alt (sgpt) ≤ 2.5 times unl, alkaline phosphatase ≤ 5 times unl
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06730295 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
What disease stage is eligible?
Stage T1-2N0M0 or RT1-2N0M0 is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages